CFDE Data Portal | Search GBX2-AS1

	Label	Description
	GBX2-AS1 Gene (Entity type)	ENSG00000233611 - GBX2 and ASB18 antisense RNA 1
	GSE148200 0 V 2 GEMCITABINE HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE128240 0 V 1 CYCLOPHOSPHAMIDE MOUSE UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE238213 dopamine 2 v 0 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE216043 cisplatin 7 v 0 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE119978 GSE180930 cisplatin 3 v 1 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE77108 saha 4 v 7 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE165960 MEK inhibition 0 v 1 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE216273 GSE216292 palbociclib 0 v 7 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE80098 GSE80366 progesterone 0 v 8 human up Gene Set (Entity type)	A Gene Set from LINCS

GBX2-AS1

ENSG00000233611 - GBX2 and ASB18 antisense RNA 1

GSE148200 0 V 2 GEMCITABINE HUMAN UP

A Gene Set from LINCS

GSE128240 0 V 1 CYCLOPHOSPHAMIDE MOUSE UP

A Gene Set from LINCS

GSE238213 dopamine 2 v 0 human up

A Gene Set from LINCS

GSE216043 cisplatin 7 v 0 human dn

A Gene Set from LINCS

GSE119978 GSE180930 cisplatin 3 v 1 human dn

A Gene Set from LINCS

GSE77108 saha 4 v 7 human up

A Gene Set from LINCS

GSE165960 MEK inhibition 0 v 1 human dn

A Gene Set from LINCS

GSE216273 GSE216292 palbociclib 0 v 7 human up

A Gene Set from LINCS

GSE80098 GSE80366 progesterone 0 v 8 human up

A Gene Set from LINCS

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.